Qiagen N.V. — Company profile
Healthcare · Diagnostics & Research · Netherlands
Last price 50.34 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.41B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Details
| Name | Qiagen N.V. |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Employees | 5500 |
| Founded | 1986 |
| Ipo Date | 1996-06-28 |
| Ceo | Jonathan Pratt |
| Country | Netherlands |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | NL0015002SN0 |
| Cusip | N72482123 |
| Cik | 0001015820 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Jonathan M. Pratt | Chief Executive Officer and Member of Management Board |
| Dr. Roland Sackers | Chief Financial Officer, MD and Member of Management Board |
| Antonio Santos | Senior Vice President and Head of Global Operations |
| Daniel Wendorff CEFA, CIIA | Vice President and Head of Investor Relations |
| John Gilardi | Vice President and Head of Corporate Communications |
| Stephany Foster | Senior Vice President and Head of Human Resources |
| Dr. Thomas Schweins | Senior Vice President of Life Science Business Area |
| Dr. Thomas Theuringer | Senior Director and Head of External Communications |
| Jean-Pascal Viola | Senior Vice President and Head of Corporate Strategy and Business Development |
| Nitin Sood | Senior Vice President and Head of Product Portfolio & Innovation |
Contact
| Address | Hulsterweg 82, Venlo, 5912 PL, Netherlands |
| Phone | 31 77 355 6600 |
| Website | https://www.qiagen.com |